YIH
ESPR

Y-Intercept (HK)’s Esperion Therapeutics ESPR Stock Holding History

Y-Intercept (HK)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,267
Closed -$49K – 1520
2024
Q1 		$49K Sell
18,267
-9,002
-33% -$21.9K ﹤0.01% 1304
2023
Q4 		$81.5K Buy
+27,269
New +$35.4K 0.01% 1127
2023
Q3 		– Sell
-109,072
Closed -$152K – 1191
2023
Q2 		$152K Buy
+109,072
New +$152K 0.02% 983

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s ESPR Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 18,267 shares — an estimated $49K sold.

Y-Intercept (HK) first reported a position in ESPR in Q2 2023 and held it in 3 quarters. The position peaked at $152K in Q2 2023. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 18,267 Esperion Therapeutics shares in Q2 2024, an estimated $49K.
  • Y-Intercept (HK) first reported a position in Esperion Therapeutics in Q2 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s Esperion Therapeutics position peaked at $152K in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.